Analysts See $1.41 EPS for Quest Diagnostics (DGX); Stockbridge Partners Lowered Realpage (RP) Position By $3.88 Million

June 20, 2017 - By Ellis Scott

Analysts expect Quest Diagnostics Inc (NYSE:DGX) to report $1.41 EPS on July, 20.They anticipate $0.07 EPS change or 5.22% from last quarter’s $1.34 EPS. DGX’s profit would be $192.84 million giving it 19.17 P/E if the $1.41 EPS is correct. After having $1.33 EPS previously, Quest Diagnostics Inc’s analysts see 6.02% EPS growth. The stock increased 0.44% or $0.47 during the last trading session, reaching $108.14. About shares traded. Quest Diagnostics Inc (NYSE:DGX) has risen 39.04% since June 20, 2016 and is uptrending. It has outperformed by 22.34% the S&P500.

Stockbridge Partners Llc decreased Realpage Inc (RP) stake by 3.43% reported in 2016Q4 SEC filing. Stockbridge Partners Llc sold 129,297 shares as Realpage Inc (RP)’s stock declined 2.46%. The Stockbridge Partners Llc holds 3.64M shares with $109.12M value, down from 3.77 million last quarter. Realpage Inc now has $3.06 billion valuation. The stock increased 5.10% or $1.8 during the last trading session, reaching $37.1. About shares traded. RealPage Inc (NASDAQ:RP) has risen 59.26% since June 20, 2016 and is uptrending. It has outperformed by 42.56% the S&P500.

Stockbridge Partners Llc increased Amazon Com Inc (NASDAQ:AMZN) stake by 62,312 shares to 119,881 valued at $89.90 million in 2016Q4. It also upped Tyler Technologies Inc (NYSE:TYL) stake by 495,628 shares and now owns 704,764 shares. Visa Inc (NYSE:V) was raised too.

Since January 4, 2017, it had 0 insider buys, and 19 selling transactions for $56.91 million activity. Chaney William P sold 10,000 shares worth $350,500. The insider Seren Capital – Ltd. sold 95,760 shares worth $3.29M. WINN STEPHEN T sold 159,600 shares worth $5.62 million. $104,100 worth of stock was sold by BERKELEY ALFRED R III on Friday, March 10. 5,000 shares valued at $175,100 were sold by HILL W BRYAN on Tuesday, March 7. Monk David G had sold 15,000 shares worth $526,200. Shares for $52,275 were sold by Glover Ashley Chaffin on Monday, March 13.

Among 2 analysts covering RealPage (NASDAQ:RP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RealPage had 4 analyst reports since June 8, 2016 according to SRatingsIntel. The rating was maintained by Benchmark on Monday, February 27 with “Buy”. The company was initiated on Tuesday, June 28 by Benchmark. The rating was upgraded by William Blair on Wednesday, June 8 to “Outperform”. Benchmark maintained it with “Buy” rating and $33 target in Monday, November 14 report.

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.11, from 1.26 in 2016Q3. It dropped, as 17 investors sold RP shares while 54 reduced holdings. 28 funds opened positions while 54 raised stakes. 50.66 million shares or 0.94% more from 50.18 million shares in 2016Q3 were reported. Dupont Cap has 0.03% invested in RealPage Inc (NASDAQ:RP) for 41,284 shares. Federated Investors Pa has invested 0.01% in RealPage Inc (NASDAQ:RP). Tower Research Ltd (Trc) owns 597 shares or 0% of their US portfolio. Palisade Mngmt Ltd Liability Corporation Nj stated it has 1.06% in RealPage Inc (NASDAQ:RP). Sawgrass Asset Management Limited Liability reported 29,225 shares. Martingale Asset Ltd Partnership stated it has 7,414 shares. Tfs Cap reported 56,089 shares stake. 395,770 are owned by Hancock Holding. Tygh Mngmt owns 206,381 shares. Horizon Kinetics Ltd Company reported 13,853 shares. Sei Invests reported 172,618 shares stake. Us Retail Bank De invested in 6,820 shares. Zacks Investment Mgmt has invested 0.05% in RealPage Inc (NASDAQ:RP). Blackrock Mngmt Limited Liability has 203,459 shares. 204,418 are owned by Morgan Stanley.

Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has market cap of $14.79 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 21.64 P/E ratio. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks , health plans, employers and accountable care organizations (ACOs).

Among 13 analysts covering Quest Diagnostics (NYSE:DGX), 6 have Buy rating, 1 Sell and 6 Hold. Therefore 46% are positive. Quest Diagnostics had 27 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Mizuho given on Friday, October 21. Canaccord Genuity maintained the shares of DGX in report on Friday, November 13 with “Buy” rating. The rating was maintained by Mizuho on Monday, June 5 with “Buy”. Zacks upgraded Quest Diagnostics Inc (NYSE:DGX) on Tuesday, August 18 to “Hold” rating. The firm earned “Neutral” rating on Thursday, March 16 by Bank of America. FBR Capital maintained the shares of DGX in report on Wednesday, April 12 with “Outperform” rating. Goldman Sachs upgraded Quest Diagnostics Inc (NYSE:DGX) on Monday, December 12 to “Buy” rating. The firm earned “Neutral” rating on Thursday, October 22 by Mizuho. As per Monday, April 24, the company rating was maintained by Raymond James. The rating was downgraded by Jyske Bank on Friday, June 24 to “Sell”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: